Zepbound is not purely a GLP-1 drug. It activates GLP-1 receptors, so it belongs to that family, but it also activates a second receptor called GIP, making it a dual incretin agonist. This distinction matters because the added GIP activity is a key reason Zepbound produces greater weight loss than GLP-1-only medications like semaglutide (Wegovy).
How Zepbound Works on Two Receptors
The active ingredient in Zepbound is tirzepatide. Your gut naturally produces two hormones after you eat: GLP-1 and GIP. Both signal your brain to reduce appetite and help regulate blood sugar, but they do so through separate receptors. Traditional GLP-1 medications like semaglutide only target one of those receptors. Tirzepatide targets both.
Interestingly, tirzepatide doesn’t treat the two receptors equally. Its binding strength at the GIP receptor matches the body’s own GIP hormone, but it binds to the GLP-1 receptor about five times more weakly than natural GLP-1. That weaker GLP-1 binding actually appears to be an advantage: it causes less receptor burnout over time, meaning the GLP-1 pathway may stay responsive longer. The GIP side of the equation contributes its own benefits, including improvements in insulin sensitivity through a mechanism that works independently of weight loss.
Weight Loss: Zepbound vs. GLP-1-Only Drugs
The dual-receptor approach translates into meaningfully larger results. In the SURMOUNT-1 trial, adults with obesity who took Zepbound for 72 weeks lost an average of 15% of their body weight at the lowest dose (5 mg), 19.5% at the middle dose (10 mg), and 20.9% at the highest dose (15 mg), all compared to about 3% for placebo.
A head-to-head trial called SURMOUNT-5 directly compared tirzepatide against semaglutide in people with obesity and no diabetes. After 72 weeks, tirzepatide produced an average weight reduction of 20.2% versus 13.7% for semaglutide. Waist circumference shrank by 18.4 cm with tirzepatide compared to 13.0 cm with semaglutide. Both differences were statistically significant. That roughly 6.5 percentage point gap in weight loss is substantial and is widely attributed to the added GIP receptor activity that pure GLP-1 drugs lack.
FDA Approval and Who Qualifies
The FDA approved Zepbound for chronic weight management on November 8, 2023. It’s indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It’s meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment.
Tirzepatide is also sold under the brand name Mounjaro for type 2 diabetes. The molecule is identical; the brand name and approved indication differ.
Dosing and What to Expect
Zepbound is a once-weekly injection you give yourself under the skin, typically in the abdomen, thigh, or upper arm. Everyone starts at 2.5 mg per week for the first four weeks. This starting dose is primarily about letting your body adjust, not about weight loss. After that, your dose increases by 2.5 mg every four weeks or longer until you reach a maintenance dose, with a maximum of 15 mg per week.
Most people spend several months titrating up. The gradual ramp helps minimize side effects, and your prescriber may hold you at a given dose longer if you’re tolerating it well and seeing results before moving higher.
Common Side Effects
Gastrointestinal symptoms are the most frequent issue, and they overlap heavily with what people experience on GLP-1-only drugs. In clinical trials for obesity, 35.5% of participants reported nausea, 21.1% had diarrhea, 20.7% experienced constipation, and 16.3% had vomiting. In the diabetes trials, where doses tended to be lower, those rates were somewhat milder: nausea affected 12% to 24% of participants, diarrhea 12% to 22%, and vomiting 2% to 13%.
These side effects are usually worst during the first few weeks at each new dose level and tend to fade as your body adapts. They’re generally rated mild to moderate in severity. Eating smaller meals and avoiding high-fat foods can help reduce nausea during the adjustment period.
Cost and Insurance Coverage
Zepbound’s price depends heavily on your insurance situation. If you have commercial insurance and qualify for Eli Lilly’s savings card program, you can pay as little as $25 for a one-month or three-month supply. Without insurance, Lilly’s direct pharmacy offers the starting 2.5 mg dose at $349 per month and the 5 mg dose at $499. Higher doses cost more: $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg, and $1,049 for the maximum 15 mg dose. Refilling within 45 days of your previous shipment locks in $499 regardless of dose, so timing matters if you’re paying out of pocket.
Why the “Dual Agonist” Label Matters
Calling Zepbound a GLP-1 isn’t wrong, but it’s incomplete. The GIP component is not a minor addition. It contributes to insulin sensitivity, helps regulate how the body processes dietary fat, and likely plays a role in the extra weight loss tirzepatide achieves over pure GLP-1 drugs. The way tirzepatide interacts with the GLP-1 receptor is also distinct from how natural GLP-1 or semaglutide does, causing less receptor desensitization over time. In practical terms, if you’re comparing Zepbound to Wegovy or Ozempic, the dual mechanism is the main pharmacological difference and the most likely explanation for the gap in clinical results.